InsiderTrades.com logo
New CBOE “special perk” helps traders target income every weekend
From DTI Trader   |   Ad
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!
Kenneth Allen Myszkowski net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Kenneth Myszkowski Biography and Net Worth

CFO of Arrowhead Pharmaceuticals
Kenneth A. Myszkowski, Chief Financial Officer, joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation, and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.

What is Kenneth Allen Myszkowski's net worth?

The estimated net worth of Kenneth Allen Myszkowski is at least $9.14 million as of June 27th, 2023. Mr. Myszkowski owns 381,704 shares of Arrowhead Pharmaceuticals stock worth more than $9,141,811 as of December 10th. This net worth estimate does not reflect any other investments that Mr. Myszkowski may own. Additionally, Mr. Myszkowski receives an annual salary of $761,550.00 as CFO at Arrowhead Pharmaceuticals. Learn More about Kenneth Allen Myszkowski's net worth.

How old is Kenneth Allen Myszkowski?

Mr. Myszkowski is currently 57 years old. There are 5 older executives and no younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals is Dr. Mark Seefeld, Head of Toxicology & VP, who is 69 years old. Learn More on Kenneth Allen Myszkowski's age.

What is Kenneth Allen Myszkowski's salary?

As the CFO of Arrowhead Pharmaceuticals, Inc., Mr. Myszkowski earns $761,550.00 per year. The highest earning executive at Arrowhead Pharmaceuticals is Dr. Christopher R. Anzalone Ph.D., CEO, President & Director, who commands a salary of $1,650,000.00 per year. Learn More on Kenneth Allen Myszkowski's salary.

How do I contact Kenneth Allen Myszkowski?

The corporate mailing address for Mr. Myszkowski and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Kenneth Allen Myszkowski's contact information.

Has Kenneth Allen Myszkowski been buying or selling shares of Arrowhead Pharmaceuticals?

Kenneth Allen Myszkowski has not been actively trading shares of Arrowhead Pharmaceuticals during the last ninety days. Most recently, Kenneth Allen Myszkowski sold 15,000 shares of the business's stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $36.20, for a transaction totalling $543,000.00. Following the completion of the sale, the chief financial officer now directly owns 381,704 shares of the company's stock, valued at $13,817,684.80. Learn More on Kenneth Allen Myszkowski's trading history.

Who are Arrowhead Pharmaceuticals' active insiders?

Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?

In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 294,387 shares worth more than $10,066,678.39. The most recent insider tranaction occured on November, 20th when insider Martin Javier San sold 19,700 shares worth more than $567,360.00. Insiders at Arrowhead Pharmaceuticals own 5.0% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.

Information on this page was last updated on 11/20/2023.

Kenneth Allen Myszkowski Insider Trading History at Arrowhead Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/27/2023Sell15,000$36.20$543,000.00381,704View SEC Filing Icon  
12/29/2022Sell30,625$40.00$1,225,000.00336,704View SEC Filing Icon  
1/5/2022Sell40,000$61.70$2,468,000.00View SEC Filing Icon  
1/12/2021Sell13,038$81.02$1,056,338.76445,446View SEC Filing Icon  
1/6/2021Sell30,625$72.44$2,218,475.00486,568View SEC Filing Icon  
10/20/2020Sell29,166$54.04$1,576,130.64456,834View SEC Filing Icon  
1/21/2020Sell40,313$49.44$1,993,074.72424,536View SEC Filing Icon  
1/6/2020Sell20,000$60.11$1,202,200.00403,592View SEC Filing Icon  
11/1/2019Sell37,884$40.85$1,547,561.40351,420View SEC Filing Icon  
5/21/2019Sell27,071$22.00$595,562.00278,536View SEC Filing Icon  
2/19/2019Sell8,000$18.00$144,000.00313,607View SEC Filing Icon  
1/17/2019Sell81,875$14.55$1,191,281.25305,607View SEC Filing Icon  
1/2/2019Sell8,333$11.98$99,829.34395,815View SEC Filing Icon  
9/6/2018Sell45,000$19.34$870,300.00335,815View SEC Filing Icon  
6/19/2018Sell20,000$14.01$280,200.00330,815View SEC Filing Icon  
5/31/2018Sell14,000$11.00$154,000.00312,215View SEC Filing Icon  
3/27/2018Sell20,000$8.00$160,000.00330,815View SEC Filing Icon  
8/23/2016Sell6,900$8.00$55,200.00128,789View SEC Filing Icon  
8/22/2016Sell13,100$8.00$104,800.00128,789View SEC Filing Icon  
12/30/2015Sell23,347$6.13$143,117.11135,000View SEC Filing Icon  
2/12/2014Sell16,000$18.77$300,320.00View SEC Filing Icon  
See Full Table

Kenneth Allen Myszkowski Buying and Selling Activity at Arrowhead Pharmaceuticals

This chart shows Kenneth Allen Myszkowski's buying and selling at Arrowhead Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $23.95
Low: $23.92
High: $25.10

50 Day Range

MA: $26.02
Low: $21.20
High: $29.12

2 Week Range

Now: $23.95
Low: $20.67
High: $42.48

Volume

913,008 shs

Average Volume

1,485,610 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78
New CBOE “special perk” helps traders target income every weekend
From DTI Trader   |   Ad
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!